• DOI:10.1067/MAI.2001.119555
• Corpus ID: 21528985

Cyclic nucleotide phosphodiesterases.

@article{Essayan2001CyclicNP,
  title={Cyclic nucleotide phosphodiesterases.},
  author={David M. Essayan},
  journal={The Journal of allergy and clinical immunology},
  year={2001},
  volume={108 5},
  pages={
          671-80
        }
}

• D. Essayan
• Published 1 November 2001
• Biology
• The Journal of allergy and clinical immunology

Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led to the development of selective inhibitors as therapeutic agents for disease states ranging from cancer and heart failure to depression and sexual dysfunction. Several PDE types have been identified as therapeutic targets for immune/inflammatory diseases. This article briefly reviews the available in vitro, preclinical, and clinical data supporting the potential for selective PDE inhibitors as immunomodulatory agents.